CMS Open Payments · Program Year 2024
SomnoMed Inc.
SomnoMed Inc. reported $20,843.62 across General Payments, Research, and Ownership to 154 physicians and teaching hospitals across 154 transactions.
- $20.8K Below-median payer
- All-tracks total
- 154 Below-median volume
- Transactions
- 154 Above-median reach
- Recipients
- #1529
- of 1,925 companies
SomnoMed Inc. reported $20,843.62 across all CMS Open Payments tracks (General + Research + Ownership) to 154 physicians and teaching hospitals in Program Year 2024 - ranking #1529 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $20,843.62, averaging $135.35 per recipient.
SomnoMed Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer somnomed-inc SomnoMed Inc.
$20.8K · #1529/1,925 · 0.0% industry · PY2024
- TOT $20.8K
- RANK #1529
- SHARE 0.0%
- TXN 154
- RCP 154
- CAT 2
- GEN $20.8K
- TOP1 11.0%
- PY 2024
Volume peers
Nearest volume peer: Paladin Technology Solutions ($20.4K)
SomnoMed Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for SomnoMed Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For SomnoMed Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 2 general-payment categories charted below, "Food and Beverage" is the largest at $16.9K across 149 transactions, 80.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads SomnoMed Inc.'s 2-category general-payment breakdown at $16.9K, 80.9% of the reported total.
How SomnoMed Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $16.9K | 149 | 80.9% |
| Consulting Fee | $4.0K | 5 | 19.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $6,645.40 (31.9%) of $20,843.62 in this company's General Payments records across 93 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for SomnoMed Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Colleen G Lance
$2,286.08 across 2 reported transactions
- 2
Brady Kent Smith
$1,327.15 across 20 reported transactions
- 3
Alexander Thomas Vaughan
$1,120.50 across 2 reported transactions
- 4
Srujal Harshad Shah
$1,000.00 across 1 reported transactions
- 5
Carrie D Sessom
$911.67 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
SomnoMed Inc.'s spend rank (#1529 of 1,925, bottom 21% by spend) and concentration rank (#1,439 of 1,838, bottom 22% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Argenx US, Inc. : $3.5M total payments, HHI 327
- DC Dental, LLC : $12.9K total payments, HHI 327
- Intra-Sana Laboratories : $291.3K total payments, HHI 327
- KLS-Martin L.P. : $5.3M total payments, HHI 326
- Evolution Surgical, Inc : $74.8K total payments, HHI 324
- Sanofi Pasteur Inc. : $1.9M total payments, HHI 323
- SomnoMed Inc. (this company) : $20.8K total payments, HHI 323
- Tolmar, Inc. : $420.1K total payments, HHI 322
- Ancora Heart, Inc. : $136.9K total payments, HHI 320
- Ucb SA : $1.1M total payments, HHI 317
- PolyNovo North America LLC : $827.7K total payments, HHI 315
- Piedmont Plus Innovation : $24.7K total payments, HHI 314
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as SomnoMed Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about SomnoMed Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with SomnoMed Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Teikoku Pharma USA, Inc.
ABC Home Medical Supply, Inc.
DentalEZ, Inc.
Hospira, Inc.
Core Surgical Group
Put this to use
SomnoMed Inc. ranks #1529 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just SomnoMed Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.